Agendia
ESMO Advances Biomarker Framework to Guide Cancer Therapy De-Intensification, Decision-Making
Premium
The framework, which ranks de-intensification biomarkers by evidence tiers, could give oncologists, patients, regulators, and payors a common system to guide their use.
Agendia Offering AI-Enabled Genomic Test for Breast Cancer in Brazil as it Eyes Global Market
Premium
The firm is offering access in Brazil to a digital assay that provides genomic insights using technology developed in a collaboration with computational pathology firm Paige.
Illumina Touts New Partnerships, Sequencing Technology at JP Morgan Healthcare Conference
The company saw strong uptake of its sequencing platforms in the clinical oncology market, a trend that is projected to continue in 2022.
Agendia to Distribute Inivata Liquid Biopsy Breast Cancer Test in North America, Europe
Agendia will receive co-exclusive rights to distribute Inivata's RaDaR assay for minimal residual disease and relapse detection in Europe and North America.
FLEX will include full transcriptome data paired with 800 data points from 10,000 patients, offering researchers the chance to study diverse patient subsets.